Dosing & Administration

Emgality offers a once-monthly, self-administered subcutaneous injection1

The Emgality Pen1:

  • Once-monthly dosing
  • No titration required
  • Latex-free
Emgality Pen Image

Recommended dosing with no titration required1a

Month 1: Initial loading dose of two 120 mg injections
Subsequent months: One 120 mg injection per month

A loading dose of 240 mg resulted in steady-state Emgality concentrations after the first dose.1

Emgality Pens Dosing image

With the Emgality loading dose, 15% of patients’ first-year therapy is administered on Day 1.1b

aThe Emgality Pen needle is 27 gauge x 1/2 inch.2

bCalculation: 240 mg loading dose + 120 mg/month x 11 months=1560 mg; 240 mg/1560 mg=0.1538 (15%).1

Emgality administration3


  • Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
  • Choose an area for injection (abdomen or thigh if self-injecting and buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within area) each month
  • Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: The 3 key administration steps3

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

3 Key Administration Steps: Uncap the pen, Place and unlock, Press and hold image
3 Key Administration Steps: Uncap the pen, Place and unlock, Press and hold image
3 Key Administration Steps: Uncap the pen, Place and unlock, Press and hold image
Telephone icon

Telephonic injection support and an injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548) Mon-Fri, 9am to 8pm ET.

Emgality comes in an easy-to-use, latex-free pen for self-administration1,4

At First Use, 94% Easy to Use image

of patients in a study agreed that the Emgality pen was "easy to use" and 96% agreed that they were confident in their ability to use it4

Patient- and caregiver-rated experiences with the pen were assessed in an open-label, 12-month study. A total of 84 patients who received once-monthly injections of Emgality 120 mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use and the respondents’ confidence in their ability to use the device.5

Watch how to use the Emgality Pen

If you or your patients have questions about Emgality, click on the “Ask Lilly” button at the top of your screen, or call 1-833-EMGALITY (1-833-364-2548) Mon-Fri, 9am to 8pm ET to talk to a healthcare provider.

How to write a prescription for Emgality

Rx Pad Maintenance Dose image and Rx Pad Starting Dose image

aLoading Dose Kits (samples) are intended to establish safety and efficacy for a patient in the office.

Discover how eligible patients can get Emgality FREE for up to 12 monthsb

bTerms and Conditions: Offer good for up to 12 months until 12/31/2020 if healthcare provider submits a prior authorization form or coverage exception request, when required, to the patient’s insurance provider. $0 monthly offer for commercially insured with insurance provider coverage, subject to wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual cap. $0 monthly offer for commercially insured without insurance provider coverage, subject to monthly and separate annual cap of wholesale acquisition cost plus usual and customary pharmacy charges. This offer is not available for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by Medicare Part D, Medicaid, TRICARE, or any other state or federal program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

References: 1.Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0060. 3. Emgality [Instructions for Use]. Indianapolis, IN: Lilly USA, LLC 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0013. 5. Data on File. Lilly USA, LLC. DOF-GZ-US-0020.

Indication and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.